# Fine-needle aspiration biopsy of thyroid nodules

## Determining when it is necessary

Jin Soo A. Song Robert D. Hart MD FRCSC

n recent decades, the incidence of thyroid cancer has risen alarmingly, becoming a common issue of diagnosis and management for primary care physicians. Papillary thyroid cancers comprise most of detected cases at 85%.1,2 This increasing rate of diagnosis is largely attributed to advances in imaging permitting early detection of subclinical tumours, as high-resolution ultrasound detects nodules in 19% to 68% of randomly selected individuals.1 Yet despite the high rates of discovery, the mortality rate of these endocrine tumours has remained stable with an excellent prognosis, as 99% of patients with nodules smaller than 20 mm are alive at 20 years.<sup>2</sup> Hence, it is imperative to strike a balance between appropriate rates of detection and intervention to minimize morbidity and mortality, without subjecting the patient to unnecessary workup and anxiety. In order to properly stratify potential risk of malignancy, ultrasound imaging findings should be corroborated with pertinent findings on clinical history and physical examination to determine which nodules should undergo fineneedle aspiration (FNA) biopsy. We present a concise summary of the key findings that should be considered when determining which thyroid nodules require subsequent investigation.

### When further investigation is required

Thyroid ultrasound and FNA biopsy based on the clinical picture are the mainstay of investigation in suspected thyroid nodules (Table 1). Increased likelihood of thyroid malignancy from clinical history and physical examination findings should prompt an ultrasound to determine FNA biopsy eligibility based on nodule size and sonographic features. Findings from the clinical history that increase the likelihood of malignancy include rapid growth of a neck mass, head and neck irradiation, total body irradiation for bone marrow transplantation, familial thyroid carcinoma, or thyroid cancer syndromes (eg, multiple endocrine neoplasia type 2, familial adenomatous polyposis, Cowden disease).1 Relevant physical examination findings suggestive of malignancy include dysphonia, dysphagia, dyspnea, regional lymphadenopathy, and fixation of the nodule to surrounding tissue.1 Measurement of serum thyroid-stimulating hormone (TSH) should be included in the initial workup of a nodule greater than 1 cm in any dimension, as recent American Thyroid Association guidelines report a positive association between serum TSH levels and increased risk of nodule malignancy and more advanced staging of thyroid cancer.1 Moreover, previous studies

NODULE FEATURES	THRESHOLD SIZE FOR FNA	LIKELIHOOD OF MALIGNANCY
High suspicion  Solid hypoechoic nodule or solid hypoechoic component of partially cystic nodule with ≥ 1 of the following features:  • Irregular margins (infiltrative, microlobulated)  • Microcalcification  • Taller-than-wide shape  • Rim calcification with small extrusive soft tissue component  • Evidence of extrathyroidal extension	≥1.0 cm	>70%-90%
Intermediate suspicion Hypoechoic solid nodule with smooth margin without the following:  • Microcalcifications  • Extrathyroidal extension  • Taller-than-wide shape	≥1.0 cm	10%-20%
Low suspicion Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid area without any ultrasonographic features	≥1.5 cm	5%-10%
<b>Very low suspicion</b> Spongiform or partially cystic without any ultrasonographic features	≥2.0 cm	<3%
Purely cystic nodules	No biopsy required	<1%

estimate a 16% chance of malignancy with TSH levels below 0.06 mIU/L; a 25% chance with levels between 0.4 and 1.39 mIU/L; and a 52% chance when levels are greater than 5.00 mIU/L.3

With respect to ultrasound, specific findings on imaging can help consolidate a decision in determining which nodules mandate FNA biopsy. Microcalcifications, hypoechogenicity, irregular margins, taller-than-wide shape, invasion of normal structures, and lymphadenopathy are all independent features highly suggestive of malignancies.1 When considering suspicious features, one should also consider Hashimoto thyroiditis in the working diagnosis, as it might masquerade as a malignant lesion. Signs of recent upper respiratory tract infections, cervical pain, elevated inflammatory markers, fever, swelling, and symptoms of hypothyroidism all allude to this benign inflammatory condition.4 Conversely, imaging reports of a predominantly cystic nodule, cholesterol deposits forming punctate, echogenic foci with ring-down or comet-tail artifacts, solid debris with septations causing a spongiform appearance, and slow growth are associated with benign thyroid nodules.1 A highly cystic composition might be particularly reassuring, as reports have cited that 88% of thyroid cancers are uniformly solid or have minimal cystic changes of less than 5%, with marked cystic changes of more than 50% occurring in only 2.5% of cancers, all of which had numerous other suspicious sonographic findings.<sup>5</sup> Table 1 presents a summary of these recommendations including categorization of nodules based on the degree of suspicious features and likelihood of malignancy. If cytology results of an FNA biopsy are nondiagnostic, the biopsy should be repeated with ultrasound guidance and on-site cytologic evaluation.

#### Conclusion

With the rising incidence but unchanged mortality rates of thyroid cancer, conservative management with greater emphasis on monitoring is the working consensus in managing thyroid nodules. This requires corroboration of clinical and imaging findings to determine the necessity of FNA biopsy. Ultimately, as most cases are benign and malignancies often follow an indolent course, judicious use of cytologic investigation and conservative management become essential for optimal clinical practice.

Mr Song is a student and Dr Hart is Associate Professor, both in the Division of Otolaryngology–Head and Neck Surgery at Dalhousie University in Halifax, NS.

#### Competing interests

None declared

- 1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133.
- 2. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ 2013;347:f4706.
- Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008;93(3):809-14. Epub 2007 Dec 26.
- 4. Lee YS, Kim HK, Chang H, Kim SM, Kim BW, Chang HS, et al. Diagnostic thyroidectomy may be preferable in patients with suspicious ultrasonography features after cytopathology diagnosis of AUS/FLUS in the Bethesda system. Medicine (Baltimore) 2015:94(51):e2183.
- Eun NL, Yoo MR, Gweon HM, Park AY, Kim JA, Youk JH, et al. Thyroid nodules with nondiagnostic results on repeat fine-needle aspiration biopsy: which nodules should be considered for repeat biopsy or surgery rather than follow-up? Ultrasonography 2016;35(3):234-43. Epub 2016 Mar 6.

This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.

This article has been peer reviewed. Can Fam Physician 2018;64:127-8

La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de février 2018 à la page e76.

We encourage readers to share some of their practice experience: the neat little tricks that solve difficult clinical situations. Praxis articles can be submitted online at http://mc.manuscriptcentral.com/cfp or through the CFP website (www.cfp.ca) under "Authors and Reviewers."